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Abstract
Coronary artery disease (CAD) is a chronic medical condition caused by 
the buildup of plaque within the coronary artery endothelium. If left 
untreated it can progress to an acute coronary syndrome (ACS) which can 
lead to myocardial ischemia and death. Statins are lipid lowering agents 
used in clinical practice for the medical management of CAD. However, 
incidence of adverse cardiovascular (CV) events still occurs despite 
optimal therapy. Currently eicosapentaenoic acid (EPA) has been 
promoted to be effective when added to statins in lowering the incidence 
of CV events in patients with hypercholesterolemia. Through an analysis 
of several published research articles, this study found that adjunct EPA is 
a viable treatment option to statin therapy in preventing the progression 
of CAD to ACS in adults over 45, although further research is 
recommended before a change in clinical practice can be made.
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Introduction
Methods
• Literature Search: November 2018; PubMed and ClinicalKey
• Search Terms: “myocardial infarction OR coronary artery disease AND 
eicosapentaenoic acid OR epa AND statin.”
DiscussionResults
The Efficacy of Adding Eicosapentaenoic Acid to Statin Monotherapy in the Prevention of 
Acute Coronary Syndrome in Patients with Coronary Artery Disease
This study has shown enough positive results to warrant a 
further investigation for the potential use of EPA with statins 
in the reduction of disease progression in patients with CAD. 
Use of adjunct EPA is a relatively safe alternative with few 
side effects, and no significant changes to baseline LDL-C. 
However, further research focusing on improved study 
designs to limit biases, more representative samples, longer 
follow-ups, larger sample sizes, and better recruitments are 
needed to improve upon the limitations found in this study. 
While the results of this study are positive, further research 
is necessary before a shift in clinical practice in the 
management and treatment of CAD can be recommended. 
Conclusion
Each study was a RCT designed to test the efficacy of adding EPA to 
statin therapy in patients with CAD to prevent progression of disease.
* Unless noted, all studies assessed for changes in lipid profiles and 
inflammatory markers via collected serum values.
1. Alfaddagh et al (2017) - Measured changes in coronary plaque volume 
via coronary computed tomographic angiography (CCTA).
2. Niki et al (2016) – Measured changes in lipid and fibrous plaque 
components via integrated backscatter intravascular ultrasound (IB-IVUS). 
3. Nishio et al (2014) – Measured changes in fibrous-cap thickness via 
optical coherence tomography (OCT).
4 Nosaka et al (2017) – Measured changes in lipid profiles only, and 
incidence of adverse cardiac events via questionnaires at follow-up.
5. Takaki et al (2011) – Measured changes in arterial thickness via 
ultrasound of the carotid artery and ankle-brachial pulse wave velocity. 
6. Toyama et al (2014) – Measured changes in endothelial dysfunction via 
ultrasonography of right brachial artery. 
7. Watanabe et al (2017) – Measured changes in coronary plaque volume 
via IB-IVUS and incidence of CV events via questionnaires.
Inclusion Criteria
• Randomized controlled trials 
(RCTs)
• Published 2008 or later
• Age: 45+
Exclusion Criteria
• Studies investigating other diseases
• Studies without a documented 
clinical trial
• Systematic reviews or meta-
analyses




• Consists of angina pectoris and 
acute coronary syndrome
• Leading cause of death in the 
United States (320,000/year)
Pathophysiology
• Chronic buildup of plaque in 
coronary artery endothelium 
leading to obstruction of blood 
flow, ischemia and infarction
Treatment
• Lifestyle modifications
• Medical Management: Cholesterol 
lowering agents, nitroglycerin, anti-
platelets, and anti-hypertensives
• Surgical Management: Angioplasty 
vs. coronary artery bypass grafting
• EPA has shown to decrease levels of 
triglycerides, inflammatory markers 














1. NS NA NS S NS S
2. NS S S S NA S
3. NS S S S NS S
4. NS S NA NA S S
5. NS S NS NA NA S
6. NS S NS NA NA S
7. NS S NS S NS S
Key: S = Significant; NS = Not Significant; NA= Results Not Available; 
LDL-C = Low-Density Lipoprotein Cholesterol; AA = Arachidonic Acid
Findings
• No significant changes in LDL-C in all 7 studies
• Significant increases in EPA/AA ratios in 6/7 studies
• Significant decreases in inflammatory markers in 2/2 
studies that measured for PTX3, a marker more specific for 
cardiac inflammation
• Significant increases in coronary artery plaque stability in 
4/4 studies measured through various imaging methods
• Significant decrease in CV outcomes found in 1 study
• Based on above findings, a reduction in progression of 
baseline CAD was found in all 7 studies.
Limitations
• Blinding: All studies were open-label RCTs
• Recruitment: 5/7 studies were single-center studies
• Bias: 6/7 studies were conducted exclusively in Japan
• Sample Size: 4/7 studies had marginal or inadequate 
sample sizes (N<100) 
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